Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity

• Váldodahkkit: Xinghua Pang (Dahkki), Zhaoliang Huang (Dahkki), Tingting Zhong (Dahkki), Peng Zhang (Dahkki), Zhongmin Maxwell Wang (Dahkki), Michelle Xia (Dahkki), Baiyong Li (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

ABSTRACTClinical studies have shown that combination therapy of antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death-1 (PD-1) significantly improves clinical benefit over PD-1 antibody alone. However, broad application of this combination has been limited by toxic...